The imidazoline derivative calmidazolium inhibits voltage-gated Ca(2+)-channels and insulin release but has no effect on the phospholipase C system in insulin producing RINm5F-cells

Biosci Rep. 1994 Jun;14(3):145-58. doi: 10.1007/BF01240247.

Abstract

The present study shows that the calmodulin antagonist calmidazolium inhibited influx of Ca2+ through voltage-gated Ca(2+)-channels in clonal insulin producing RINm5F-cells. The mechanism of inhibition may involve both Ca(2+)-calmodulin-dependent protein kinases and direct binding of calmidazolium to the Ca(2+)-channel. Calmidazolium did not affect uptake of Ca2+ into intracellular Ca(2+)-pools, inositol 1,4,5-trisphosphate (InsP3) formation or action on intracellular Ca(2+)-pools. The calmodulin inhibitor also did not affect glucose utilization or oxidation in RINm5F-cells, speaking against an unspecific toxic effect of the compound. KCl-and ATP-stimulated insulin release from RINm5F-cells was attenuated by calmidazolium, whereas basal hormone secretion was unaffected.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Calcium / analysis
  • Calcium Channel Blockers*
  • Calmodulin / antagonists & inhibitors
  • Clone Cells
  • Glucose / analysis
  • Imidazoles / pharmacology*
  • Inositol 1,4,5-Trisphosphate / analysis
  • Insulin / metabolism*
  • Insulin Secretion
  • Islets of Langerhans / drug effects
  • Patch-Clamp Techniques
  • Rats
  • Type C Phospholipases / antagonists & inhibitors*

Substances

  • Calcium Channel Blockers
  • Calmodulin
  • Imidazoles
  • Insulin
  • calmidazolium
  • Inositol 1,4,5-Trisphosphate
  • Type C Phospholipases
  • Glucose
  • Calcium